Effects of the PPAR-γ agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 3, 2006, Pages 175-180

  Lansang, M Cecilia ^a   Coletti, Caroline ^b   Ahmed, Sofia ^b   Gordon, Michael S ^b   Hollenberg, Norman K ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Diabetes; PPAR gamma; Renin angiotensin system; Thiazolidinedione

Indexed keywords

ALDOSTERONE; CAPTOPRIL; NATRIURETIC FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RENIN; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE CALCULATION; DRUG MECHANISM; DRUG WITHDRAWAL; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT DURATION;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PPAR GAMMA; RENAL CIRCULATION; RENIN-ANGIOTENSIN SYSTEM; THIAZOLIDINEDIONES;

EID: 33750978124     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.028     Document Type: Article

References (31)

1. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazonc therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004;27:484-90.
2. Bloomgarden ZT. Thiazolidinediones. Diabetes Care 2005;28:488-93.
3. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15.
4. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001;50:1193-6.
5. Nakamura T, Ushiyama C, Suzuki S et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001;18: 308-13.
6. Pistrosch F, Herbrig E, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005;54:2206-11.
7. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12.
8. Price DA, Fisher ND, Osei SY, Lansang MC, Hollenberg NK. Renal perfusion and function in healthy African Americans. Kidney Int 2001;59:1037-43.
9. Lansang MC, Osei SY, Price DA, Fisher ND, Hollenberg NK. Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan. Hypertension 2000;36: 834-8.
10. Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 2000;36: 122-61.
11. De'Oliveira JM, Price DA, Fisher ND et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 1997;52:771-7.
12. Lansang MC, Price DA, Laffel LM et al. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001;59:1432-8.
13. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(Suppl 1):S5-S10.
14. Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, Tomino Y. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 2004;53:1473-9.
15. Baylis C, Atzpodien EA, Freshour G, Engels K. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003;307:854-60.
16. Harte A, McTernan P, Chetty R et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 2005;111:1954-61.
17. Bjorck S, Delin K, Herlitz H, Larsson O, Aurell M. Renin secretion in advanced diabetic nephropathy. Scand J Urol Nephrol Suppl 1984;79:53-7.
18. Christlieb AR, Kaldany A, D'Elia JA. Plasma renin activity and hypertension in diabetes mellitus. Diabetes 1976;25:969-74.
19. Fisher ND, Price DA, Litchfield WR, Williams GH, Hollenberg NK. Renal response to captopril reflects state of local renin system in healthy humans. Kidney Int 1999;56:635-41.
20. Price DA, Porter LE, Gordon M et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999;10:2382-91.
21. Price DA, De'Oliveira JM, Fisher ND, Williams GH, Hollenberg NK. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens 1999;12:348-55.
22. Lansang MC, Stevanovic R, Price DA, Laffel LM. Hollenberg NK. ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus. Kidney Int 2005;67:1033-7.
23. Price DA, Lansang MC, Osei SY, Fisher ND, Laffel LM, Hollenberg NK. Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan. Diabet Med 2002;19:858-61.
24. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M. Effects of the peroxisonial proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004;89:1140-5.
25. Lewis EJ. Angiotensin-converting enzyme inhibitors: considerations regarding proteinuria. Am J Kidney Dis 1987;10(1 Suppl 1):30-8.
26. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
27. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
28. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
29. Lansang MC, Osei SY, Coletti C, Krupinski J, Hollenberg NK. Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways. JRAAS 2002;3:19-23.
30. Lansang MC, Hollenberg NK. Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: are the forces leading to vasodilation and vasoconstriction linked? Diabetes 2002;51:2025-8.
31. Yosefy C, Magen E, Kiselevich A et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004;44:215-22.